An Tian, Zhang Xin-Qing, Liu Yu-Fei, Lian Juan, Wu Yan-Xiang, Lv Bo-Han, Liang Cong, Chen Chun-You, Yu Qi-Shuai, Ma Meng-Hua, Wang Yin-Qian, Jiang Guang-Jian, Fan Tao
School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, P.R. China.
Department of Neurosurgery, ChuiYangLiu Hospital Affiliated to Tsinghua University, Beijing 100022, P.R. China.
Oncol Lett. 2020 Dec;20(6):371. doi: 10.3892/ol.2020.12234. Epub 2020 Oct 21.
MicroRNAs (miRNAs) are involved in the development of several types of tumor; however, their role in spinal gliomas remains unknown. The present study aimed to identify potentially novel spinal cord gliomas (SCG)-associated miRNAs and to characterize their roles in the development and progression of SCG. miRNA expression levels in low-grade SCG (classed as stage I-II SCG based on the World Health Organization grading system), high-grade SCG (classed as stage IV SCG based on the World Health Organization grading system) and 5 control cases were measured using a miRNA expression microarray. Subsequently, blood samples from the spinal cord of patients with differing grades of SCG were screened for differentially expressed miRNAs (DEmiRNAs). Compared with the control group, 7 upregulated and 36 downregulated miRNAs were identified in the low-grade SCG group and a total of 70 upregulated and 20 downregulated miRNAs were identified in the high-grade SCG group (P≤0.05, fold change >2). Gene Ontology analysis revealed that the regulation of cellular metabolic processes, negative regulation of biological processes and axon guidance were primarily involved. Moreover, pathway analysis showed that the target genes of DEmiRNAs were enriched in tumor-related signaling pathways, such as the MAPK and Wnt signaling pathway. The results suggest that DEmiRNAs in peripheral blood may serve as novel target markers with high specificity and sensitivity for the diagnosis of SCG.
微小RNA(miRNA)参与多种类型肿瘤的发生发展;然而,它们在脊髓胶质瘤中的作用尚不清楚。本研究旨在鉴定潜在的新型脊髓胶质瘤(SCG)相关miRNA,并阐明其在SCG发生发展过程中的作用。使用miRNA表达微阵列检测低级别SCG(根据世界卫生组织分级系统分类为I-II期SCG)、高级别SCG(根据世界卫生组织分级系统分类为IV期SCG)和5例对照病例中的miRNA表达水平。随后,对不同级别SCG患者脊髓的血液样本进行差异表达miRNA(DEmiRNA)筛选。与对照组相比,低级别SCG组中鉴定出7个上调和36个下调的miRNA,高级别SCG组中总共鉴定出70个上调和20个下调的miRNA(P≤0.05,变化倍数>2)。基因本体分析显示,主要涉及细胞代谢过程的调控、生物过程的负调控和轴突导向。此外,通路分析表明,DEmiRNA的靶基因富集于肿瘤相关信号通路,如MAPK和Wnt信号通路。结果表明,外周血中的DEmiRNA可能作为诊断SCG的具有高特异性和敏感性的新型靶标标志物。